|
ANVS | Annovis Bio, Inc. |
|
|
ANVS | Annovis Bio, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.43 |
| Leverage | 23.46% |
| Market Cap | $ 30.4m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -24.9m |
| Margin | -1430.13% |
Annovis Bio, Inc., a clinical-stage drug platform company, develops drugs to treat neurodegeneration. The company is headquartered in Berwyn, Pennsylvania.